Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration

International Journal of Toxicology

Volumn 18, Issue 5, 1999, Pages 337-352

  Teo, Steve K ^a   Trigg, Nancy J ^b   Shaw, Mary E ^b   Morgan, J Michael ^c   Thomas, Steve D ^a  

^a CELGENE CORPORATION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NONE

Author keywords

Oral; Rodents; Subchronic toxicology; Thalidomide

Indexed keywords

THALIDOMIDE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; LEUKOPENIA; MALE; MOUSE; MUSCLE STRENGTH; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TOXICITY TESTING;

ANIMALIA; RODENTIA;

EID: 0032723954     PISSN: 10915818     EISSN: None     Source Type: Journal    
DOI: 10.1080/109158199225251     Document Type: Review

References (29)

1. Braun, A., F. Harding, and S. Weinreb. 1986. Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharm. 82:175-179.
2. Brumer, R. 1992. Spontaneous corneal dystrophy and generalized basement membrane changes in the Fischer-344 rats. Toxicol. Pathol. 20:357-366.
3. D'Amato, R. J., M. S. Loughnan, E. Flynn, and J. Folkman. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91:4082-4085.
4. Eriksson, T., S. Bjorkman, B. Roth, A. Fyge, and P. Hoglund. 1995. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44-52.
5. Esser, H., and F. Heinzler. 1956. Klinishe erfahrungen mit einem neuen Sedativum und Hypnotikum. Therapie der Gegenwart 95:374-376.
6. Fabro, S., R. Smith, and R. Williams. 1967. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215:296.
7. Georghiou, P., and A. Allworth. 1992. Thalidomide in painful AIDS-associated proctitis. J. Infect. Dis. 166:939-940.
8. Girardin, E., G. Grau, J. Dayer, P. Roux-Lombard, The J5 Study Group, and P. Lambert. 1988. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319:397-400.
9. Gunzler, V. 1992. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Safety 7:116-134.
10. Hess, C., T. Hunziker, A. Kupfer, and H. Ludin. 1986. Thalidomide-induced peripheral neuropathy: A prospective clinical, neurophysiological and pharmacogenetic evaluation. J. Neurol. 233:83-89.
11. ICH Guidance for Industry. 1997. M3 Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals, Food and Drug Administration, U.S. Department of Health and Human Services.
12. Koch, H. 1985. Thalidomide and congeners as anti-inflammatory agents. Pro. Med. Chem. 22:165-242.
13. Kuhn, W., and E. Van Maanen. 1961. Central nervous system effects of thalidomide. J. Pharmacol. Exp. Ther. 134:60-68.
14. Kunz, W., H. Keller, and H. Muckter. 1956. N-phthalylglutamineaure-imid: Experimentelle untersuchungen an einem neuen synthetischen produkt mit sedativen eigenschaften. Arzneim. Forsch. 6:426-430.
15. Locker, D., E. Superstine, and F. Sulman. 1971. The mechanism of the push and pull principle. VIII: Endocrine effects of thalidomide and its analogues. Arch. Intl. Pharmacodyn. Ther. 194:39-55.
16. Mellin, G. W., and M. Katzenstein. 1962. The saga of thalidomide: Neuropathy to embropathy, with case reports and congenital abnormalities. N. Eng. J. Med. 267:1184-1193.
17. Meyer, O. A., H. A. Tilson, W. C. Byrd, and M. T. Riley. 1979. A method for the routine assessment of fore-and hindlimb grip strength of rats and mice. Neurobehav. Toxicol. 3:233-236.
18. Mitsumori, K., and G. A. Boorman. 1990. Spinal cord and peripheral nerves. In Pathology of the Fischer rat - reference and atlas, eds., G. A. Boorman, S. L. Eustis, and M. R. Elwell, 179-191. San Diego, CA: Academic Press.
19. Moreira, A., E. Sampaio, A. Zmuidzinas, P. Frindt, K. Smith, and G. Kaplan. 1993. Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation. J. Exp. Med. 177:1675-1680.
20. Murdoch, J., and G. Campbell. 1958. Antithyroid activity of N-phthalylglutamic acid imide (K17). Br. Med. J. 1:84-85.
21. NIH. 1985. Guide for the care and use of laboratory animals. DHEW, Publication No. (NIH) 86-23. Revised 1985.
22. Schumacher, H., R. Smith, and R. Williams., 1965a. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25:338-351.
23. Schumacher, H., R. Smith, and R. Williams. 1965b. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25:324-337.
24. Sheskin, J. 1965. Thalidomide in the treatment of lepra reaction, din. Pharmacol. Therap. 6:303-306.
25. Somers, G. 1960. Pharmacological properties of thalidomide (a-phthalimido glutarimide), a new sedative hypnotic drug. Br. J. Pharmacol. 15:111-116.
26. Tracey, K., H. Wei, K. Manogue, Y. Fong, D. Hesse, H. Nguyen, G. Kuo, B. Beutler, R. Cotran, A. Cerami, and S. Lowry. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J. Exp. Med. 167:1211-1227.
27. Vogelsang, G., E. Farmer, A. Hess, V. Altamonte, W. Beschorner, D. Jabs, R. Corio, L. Levin, O. Colvin, J. Wingard, and G. Santos. 1992. Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326:1055-1058.
28. Williams, R., H. Schumacher, S. Fabro, and R. Smith. 1965. Embryopathic activity in drugs. London: J. A. Churchill Ltd.
29. Youle, M., C. Clarbour, C. Farthing, M. Connolly, D. Hawkins, R. Staughton, and B. Gazzard. 1989. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br. Med. J. 298:432.